|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
|
|
|
|
|
Exhibit Number
|
|
Exhibit Title or Description
|
|
|
|
|
Press Release, dated October 26, 2023
|
|
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
CATALYST BIOSCIENCES, INC.
|
|
|
|
|
Date: October 27, 2023
|
By:
|
/s/ Nassim Usman, Ph.D.
|
|
Name:
|
Nassim Usman, Ph.D.
|
|
Title:
|
President and Chief Financial Officer
|
Company Name:
|
GNI Group Ltd.
|
|
Representative:
|
Director, Representative Executive Officer,
President and CEO Ying Luo, PhD
|
|
(Security Code: 2160, TSE Growth)
|
||
Contact Person:
|
Chief Financial Officer
Toshiya Kitagawa
|
|
(TEL. 03-6214-3600)
|
Document and Entity Information |
Oct. 26, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Oct. 26, 2023 |
Entity File Number | 000-51173 |
Entity Registrant Name | Catalyst Biosciences, Inc. |
Entity Central Index Key | 0001124105 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 56-2020050 |
Entity Address, Address Line One | 12730 High Bluff Drive |
Entity Address, Address Line Two | Suite 250 |
Entity Address, City or Town | San Diego |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92130 |
City Area Code | 650 |
Local Phone Number | 266-8674 |
Title of 12(b) Security | Common Stock |
Trading Symbol | CBIO |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
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end
7:%8T*X/.0)O:;Y .3DM,2YH=&U02P4& 4 !0!+ 0 3#,
end
"JT
M9HWD=PFC#>)A*PM9J#VYU8&Y#D!7%9Z(^C<7\P=^O:)\TL4\5T2H!_8 GJ2(
MZ7-"04=?=&2C2QR